Oral Nicotine Product Messaging to Communicate Risk of Use for Young Adults

Summary

This clinical trial tests the effect of different types of oral nicotine pouch (ONP) messaging to communicate risk of using these products for young adults. Tobacco use remains the leading preventable cause of death due to cancer and other outcomes in the U.S. Tobacco products vary in the health risks they pose to users. Combustible tobacco products such as cigarettes pose higher risks than noncombustible nicotine and tobacco products such as ONPs. Despite the lower harm potential of ONPs for those who use tobacco, there are potential risks to non-users, especially susceptible young adults. Different types of messaging that include information about absolute risk and addiction, risks of ONPs relative to cigarettes and e-cigarettes, ability to use ONPs instead of cigarettes/e-cigarettes (switching), and the potential benefits of doing so and potential benefits of switching to ONPs may be more or less effective in communicating risk for young adults.

Conditions

• Tobacco-Related Carcinoma

Interventions

BEHAVIORAL

Behavioral Intervention

Receive messaging regarding addiction beliefs

BEHAVIORAL

Behavioral Intervention

Receive messaging regarding relative risk beliefs about the risks of ONPs relative to cigarettes and e-cigarettes

BEHAVIORAL

Behavioral Intervention

Receive messaging regarding self and response efficacy beliefs about ability to use ONPs instead of cigarettes/e-cigarettes and the potential benefits of doing so

BEHAVIORAL

Behavioral Intervention

Receive messaging regarding switching beliefs about the potential benefits of switching to ONPs

OTHER

Survey Administration

Ancillary studies

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• Ohio State University Comprehensive Cancer Center

  lead OTHER

Principal Investigators

• Mahmood Alalwan, PhD · Ohio State University Comprehensive Cancer Center

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

30 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2025-08-01

Primary Completion

2025-12-29

Completion

2025-12-29

Countries

• United States

Study Locations